Director of Clinical Trials
Associate Professor of Urology
Director of Clinical Trials
Associate Professor of Urology
employing advanced surgical procedures including the use of robotic surgery to maximize the quality of life for people with urologic malignancies.
Marc Bjurlin, DO received his medical degree from Midwestern University and completed his residency at the Cook County Hospital in Chicago. After residency, Dr Bjurlin completed a fellowship in urologic oncology at New York University along with a master of science degree in clinical investigation through the New York University School of Medicine. Prior to joining UNC, Dr. Bjurlin was Assistant Professor of Urology and Director of Urologic Oncology at NYU Langone Hospital in Brooklyn and was recently selected by Super Doctors for a “Rising Star” distinction in the New York Metro area.
Dr. Bjurlin’s clinical practice is focused on urologic oncology—in particular, the treatment of bladder, prostate, testis, and kidney cancer. He is a member of the integrated Multidisciplinary Genitourinary Oncology Group at the Lineberger Comprehensive Cancer Center. His team takes a collaborative approach to create a personalized treatment. Dr. Bjurlin’s expertise has allowed him to serve on national committees that establish care guidelines for the management of cancers of the urinary tract including the American Urological Association’s committee on the Standard Operating Procedure for Prostate Magnetic Resonance Imaging.
In addition to patient care, Dr. Bjurlin participates in research focused on employing advanced surgical procedures including the use of robotic surgery to maximize the quality of life for people with urologic malignancies. He is also a member of the American Urological Association New Technology and Imaging Committee.
Congratulations to Heather Schultz, NP, FAUNA, Marc Bjurlin, DO, MSc, FACOS, and Dr. Matthew Nielsen, MD, MS, FACS for receiving the UNC Health 2024 “Award for Carolina Excellence”
A multi-center Phase 3 clinical trial named “QUILT” is exploring a potential new treatment that involves administering BCG (Bacillus Calmette-Guerin) combined with an experimental drug known as N-803 (Nogapendekin alfa inbakicept), with the goal of p … Read more
American College of Osteopathic Medicine & Surgery, Chicago, IL
Cook County Health and Hospitals, Chicago, IL
NYU School of Medicine, New York, NY
